OncoMatch/Clinical Trials/NCT03401294
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Is NCT03401294 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies FOLFOXIRI and Bevacizumab for metastatic colorectal cancer.
Treatment: FOLFOXIRI and Bevacizumab — Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
WHO 0–1
Demographics
Prior therapy
Lab requirements
Blood counts
adequate functioning of the bone marrow
Kidney function
adequate functioning of the kidneys
Liver function
adequate functioning of the liver
Adequate functioning of the bone marrow, liver, and kidneys.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03401294 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages